Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup A/C/W-135/Y polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.
%0 Journal Article
%1 harrison_prospects_2006
%A Harrison, Lee H
%D 2006
%J Clinical Microbiology Reviews
%K Adolescent, Adult, Aged, Child, Conjugate Design, Drug Humans, Infections, Meningococcal Middle Neisseria Preschool, Serotyping, Vaccination, Vaccines, meningitidis,
%N 1
%P 142--164
%R 10.1128/CMR.19.1.142-164.2006
%T Prospects for vaccine prevention of meningococcal infection
%U http://www.ncbi.nlm.nih.gov/pubmed/16418528
%V 19
%X Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup A/C/W-135/Y polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.
@article{harrison_prospects_2006,
abstract = {Neisseria meningitidis is the leading cause of bacterial meningitis in the United States and worldwide. A serogroup {A/C/W-135/Y} polysaccharide meningococcal vaccine has been licensed in the United States since 1981 but has not been used universally outside of the military. On 14 January 2005, a polysaccharide conjugate vaccine that covers meningococcal serogroups A, C, W-135, and Y was licensed in the United States for 11- to 55-year-olds and is now recommended for the routine immunization of adolescents and other high-risk groups. This review covers the changing epidemiology of meningococcal disease in the United States, issues related to vaccine prevention, and recommendations on the use of the new vaccine.},
added-at = {2011-03-11T10:05:34.000+0100},
author = {Harrison, Lee H},
biburl = {https://www.bibsonomy.org/bibtex/21e2176864df5142ab9c10b8bc0c119b5/jelias},
doi = {10.1128/CMR.19.1.142-164.2006},
interhash = {a36ae89551cf210eb7b59c193ef8c662},
intrahash = {1e2176864df5142ab9c10b8bc0c119b5},
issn = {0893-8512},
journal = {Clinical Microbiology Reviews},
keywords = {Adolescent, Adult, Aged, Child, Conjugate Design, Drug Humans, Infections, Meningococcal Middle Neisseria Preschool, Serotyping, Vaccination, Vaccines, meningitidis,},
month = jan,
note = {{PMID:} 16418528},
number = 1,
pages = {142--164},
timestamp = {2011-03-11T10:05:53.000+0100},
title = {Prospects for vaccine prevention of meningococcal infection},
url = {http://www.ncbi.nlm.nih.gov/pubmed/16418528},
volume = 19,
year = 2006
}